IP Library Patent Application 10551302
Patent Application
App. No. 10/551,302

Modulation of cell death

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/551,302
Abstract

A method of modulating cell death includes administering pyridoxal-5′phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.

Claims (100)

1 . A method of modulating cell death comprising administering a therapeutically effective amount of at least one of pyridoxal-5′-phosphate, pyridoxic acid, pyridoxal, pyridoxine, or pyridoxamine.

2 . A method of modulating cell death comprising administering a therapeutically effective amount of at least one compound of the formula

wherein

R 1 is alkyl or alkenyl, in which alkyl or alkenyl can be interrupted by nitrogen, oxygen, or sulfur, and can be substituted at the terminal carbon by hydroxy, alkoxy, alkanoyloxy, alkanoyloxyaryl, alkoxyalkanoyl, alkoxycarbonyl, or dialkylcarbamoyloxy;

alkoxy;

dialkylamino;

alkanoyloxy;

alkanoyloxyaryl;

alkoxyalkanoyl;

alkoxycarbonyl;

dialkylcarbamoyloxy;

aryl, aryloxy, arylthio, or aralkyl,in which aryl can be substituted by alkyl, alkoxy, amino, hydroxy,halo, nitro, or alkanoyloxy; or

a pharmaceutically acceptable salt thereof.

3 . The method of claim 2 , wherein said R 1 is phenyl or naphthyl in which phenyl or naphthyl is unsubstituted or substituted by one or more groups of C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, halo, nitro, or C 1-4 alkanoyloxy.

4 . The method of claim 2 , wherein said R 1 is (2-acetoxy-2-methyl)propanyl, dimethylamino, or 1-ethanoyloxy-1-methylethyl.

5 . The method of claim 2 , wherein said R 1 is tert-butyl.

6 . The method of claim 2 , wherein said R 1 is methoxy or ethoxy.

7 . The method of claim 2 , wherein said R 1 is toluyl, naphthyl, phenyl, acetylphenyl, or 1-ethanoyloxyphenyl.

8 . The method of claim 2 , wherein said R 1 is acetylsalicyl, dimethylamino, or 2,2-dimethylethyl.

9 . The method of claim 2 , wherein said compound is 2-methyl-3-toluoyloxy-4-formyl-5-hydroxymethylpyridine.

10 . The method of claim 2 , wherein said compound is 2-methyl-3-β-naphthoyloxy-4-formyl-5-hydroxymethylpyridine.

11 . A method of modulating cell death comprising administering a therapeutically effective amount of at least one compound of the formula

wherein

R 1 is alkyl or alkenyl, in which alkyl or alkenyl can be interrupted by nitrogen, oxygen, or sulfur, and can be substituted at the terminal carbon by hydroxy, alkoxy, alkanoyloxy, alkanoyloxyaryl, alkoxyalkanoyl alkoxycarbonyl, or dialkylcarbamoyloxy,

alkoxy,

dialkylamino;

alkanoyloxy,

alkanoyloxyaryl;

alkoxyalkanoyl;

alkoxycarbonyl;

dialkylcarbamoyloxy;

aryl, aryloxy, arylthio, or aralkyl,in which aryl can be substituted by alkyl, alkoxy, amino, hydroxy,halo, nitro, or alkanoyloxy, and

R 2 is a secondary amino group; or

a pharmaceutically acceptable salt thereof.

12 . The method of claim 11 , wherein said R 1 is phenyl or naphthyl in which phenyl or naphthyl is unsubstituted or substituted by one or more groups of C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, halo, nitro, or C 1-4 alkanoyloxy.

13 . The method of claim 11 , wherein said R 1 is (2-acetoxy-2-methyl)propanyl, dimethylamino, or 1-ethanoyloxy-1-methylethyl.

14 . The method of claim 11 , wherein said wherein R 1 is tert-butyl.

15 . The method of claim 11 , wherein said wherein R 1 is methoxy or ethoxy.

16 . The method of claim 11 , wherein said R 1 is toluyl, naphthyl, phenyl, or 1-ethanoyloxyphenyl.

17 . The method of claim 11 , wherein said R 1 is dimethylamino, acetylsalicyl, or 2,2-dimethylethyl.

18 . The method of claim 11 , wherein said R 2 is a group of the formula

wherein R 3 and R 4 are each independently alkyl or when taken together form a ring with the nitrogen atom and which ring may optionally be interrupted by a nitrogen or oxygen atom.

19 . The method of claim 11 , wherein said R 2 is piperidino.

20 . The method of claim 11 , wherein said R 2 is morpholino or piperazino.

21 . The method of claim 11 , wherein said compound is 1-morpholino-1,3-dihydro-7-(p-toluoyloxy)-6-methylfuro(3,4-c)pyridine.

22 . The method of claim 11 , wherein said compound is 1-morpholino-1,3-dihydro-7-(β-naphthoyloxy)-6-methylfuro(3,4-c)pyridine.

23 . The method of claim 11 , wherein said compound is 1-morpholino-1,3-dihydro-7-pivaloyloxy-6-methylfuro(3,4-c)pyridine.

24 . The method of claim 11 , wherein said compound is 1-morpholino-1,3-dihydro-7-(dimethylcarbamoyloxy-6-methylfuro(3,4-c)pyridine.

25 . The method of claim 11 , wherein said compound is 1-morpholino-1,3-dihydro-7-acetylsalicyloxy-6-methylfuro(3,4-c)pyridine.

26 . A method of modulating cell death comprising administering a therapeutically effective amount of at least one compound of the formula

wherein

R 1 is hydrogen or alkyl;

R 2 is —CHO, —CH 2 OH, —CH 3 , —CO 2 R 6 in which R 6 is hydrogen, alkyl, or aryl;

or

R 2 is —CH 2 —O-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R 1 ;

R 3 is hydrogen and R 4 is hydroxy, halo, alkoxy, alkanoyloxy, alkylamino or arylamino; or

R 3 and R 4 are halo; and

R 5 is hydrogen, alkyl, aryl, aralkyl, or —CO 2 R 7 in which R 7 is hydrogen, alkyl, aryl, or aralkyl;

or a pharmaceutically acceptable salt thereof.

27 . The method of claim 26 , wherein said R 1 is hydrogen.

28 . The method of claim 26 , wherein said R 2 is —CH 2 OH, or —CH 2 —O-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R 1 .

29 . The method of claim 26 , wherein said R 3 is hydrogen and R 4 is F, MeO—, or CH 3 C(O)O—.

30 . The method of claim 26 , wherein said R 3 and R 4 are F.

31 . The method of claim 26 , wherein said R 5 is alkyl or aralkyl.

32 . The method of claim 26 , wherein said R 5 is t-butyl or benzyl.

33 . A method of claim 26 , wherein said compound is

34 . A method modulating cell death comprising administering a therapeutically effective amount of at least one compound of the formula

wherein

R 1 is hydrogen or alkyl;

R 2 is —CHO, —CH 2 OH, —CH 3 or CO 2 R 5 in which R 5 is hydrogen, alkyl, or aryl; or

R 2 is —CH 2 O-alkyl- (in which alkyl is covalently bonded to the oxygen at the 3-position instead of R 1 );

R 3 is hydrogen, alkyl, aryl, or aralkyl;

R 4 is hydrogen, alkyl, aryl, aralkyl, or —CO 2 R 6 in which R 6 is hydrogen, alkyl, aryl, or aralkyl; and

n is 1 to 6;

or a pharmaceutically acceptable salt thereof

35 . The method of claim 34 , wherein said R 1 is hydrogen.

36 . The method of claim 34 , wherein said R 2 is —CH 2 OH, or —CH 2 —O-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R 1 .

37 . The method of claim 34 , wherein said R 3 is hydrogen.

38 . The method of claim 34 , wherein said R 4 is alkyl or H.

39 . The method of claim 34 , wherein said R 4 is ethyl.

40 . The method of claim 34 , wherein said compound is

41 . A method modulating cell death comprising administering a therapeutically effective amount of at least one compound of the formula

in which

R 1 is hydrogen or alkyl;

R 2 is —CHO, —CH 2 OH, —CH 3 or —CO 2 R 8 in which R 8 is hydrogen, alkyl, or aryl; or

R 2 is —CH 2— O-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R 1 ;

R 3 is hydrogen and R 4 is hydroxy, halo, alkoxy or alkanoyloxy; or

R 3 and R 4 can be taken together to form ═O;

R 5 and R 6 are hydrogen; or

R 5 and R 6 are halo; and

R 7 is hydrogen, alkyl, aryl, aralkyl, or —CO 2 R 8 in which R 8 is hydrogen, alkyl, aryl, or aralkyl;

or a pharmaceutically acceptable salt thereof.

42 . The method of claim 41 , wherein R 1 is hydrogen.

43 . The method of claim 41 , wherein R 2 is —CH 2 O or —CH 2 —O-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R 1 .

44 . The method of claim 41 , wherein said R 4 is —OH or CH 3 C(O)O—.

45 . The method of claim 41 , wherein said R 3 and R 4 taken together form ═O.

46 . The method of claim 41 , wherein said R 5 and R 6 are F.

47 . The method of claim 41 , wherein said R 7 is alkyl.

48 . The method of claim 41 , wherein said R 7 is ethyl.

49 . The method of claim 41 , wherein said compound is

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jul 26, 2011
From: BIRMINGHAM ASSOCIATES LTD.
To: MEDICURE INC.
Reel/Frame 026653/0037 →
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2008
From: GE CANADA ASSET FINANCE HOLDING COMPANY, SUCCESSOR AS AGENT TO MERRILL LYNCH CAPITAL CANADA INC.
To: MEDICURE INC.
Reel/Frame 021924/0657 →
SECURITY AGREEMENT Recorded Sep 21, 2007
From: MEDICURE INC.
To: BIRMINGHAM ASSOCIATES LTD.
Reel/Frame 019864/0092 →
SECURITY AGREEMENT Recorded Aug 15, 2006
From: MEDICURE INC.
To: MERRILL LYNCH CAPITAL CANADA INC.
Reel/Frame 018109/0062 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2005
From: FRIESEN, ALBERT DAVID
To: MEDICURE INC.
Reel/Frame 017085/0100 →